REVBREVELATION BIOSCIENCES, INC.
- AccessWire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to ...
- AccessWire
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to ...
- AccessWire
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to ...
- AccessWire
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to ...
- AccessWire
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and ...
- AccessWire
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and ...
- AccessWire
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and ...
- AccessWire
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and ...
- AccessWire
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30, ...
- AccessWire
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing inflammation to optimize ...
- AccessWire
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing inflammation to optimize ...
- AccessWire
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing inflammation to optimize ...
- AccessWire
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company that is focused on rebalancing inflammation, today ...
- AccessWire
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing ...
- AccessWire
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company that is focused on rebalancing ...
- AccessWire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company that is focused on ...
- AccessWire
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing ...
- SEC
8-K Form - Current report, items 7.01 and 9.01 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Current report, items 7.01 and 9.01 ...
- AccessWire
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
SAN DIEGO, CA, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing ...
- SEC
EFFECT Form - Notice of Effectiveness - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Notice of Effectiveness ...
- SEC
424B3 Form - Prospectus [Rule 424(b)(3)] - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Prospectus [Rule 424(b)(3)] ...
- SEC
DEF 14A Form - Other definitive proxy statements - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Other definitive proxy statements ...
- SEC
S-3 Form - Registration statement under Securities Act of 1933 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Registration statement under Securities Act of 1933 ...
- SEC
8-K Form - Current report, items 1.01, 3.02, 3.03, 8.01, and 9.01 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Current report, items 1.01, 3.02, 3.03, 8.01, and 9.01 ...
- SEC
PRE 14A Form - Other preliminary proxy statements - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Other preliminary proxy statements ...